Wedbush Reiterates Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities researchers at Wedbush in a research report issued on Monday,RTT News reports. They currently have a $23.00 price objective on the stock. Wedbush's target price suggests a potential upside of 339.77% from the company's current price.

A number of other brokerages have also recently commented on YMAB. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Oppenheimer assumed coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an "outperform" rating and a $23.00 price target on the stock. Finally, Brookline Capital Management started coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a "buy" rating and a $17.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $19.30.

Y-mAbs Therapeutics Stock Down 0.4 %

Shares of NASDAQ YMAB traded down $0.02 during midday trading on Monday, hitting $5.23. 164,817 shares of the company's stock were exchanged, compared to its average volume of 466,956. Y-mAbs Therapeutics has a 12 month low of $4.25 and a 12 month high of $18.10. The firm has a market capitalization of $234.25 million, a PE ratio of -9.76 and a beta of 0.65. The company's 50 day moving average price is $6.34 and its 200 day moving average price is $10.54.

Remove Ads

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The firm had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period last year, the business earned ($0.02) earnings per share. On average, equities research analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC acquired a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at about $22,408,000. Caligan Partners LP grew its position in shares of Y-mAbs Therapeutics by 105.3% during the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company's stock valued at $15,718,000 after acquiring an additional 613,175 shares during the period. State Street Corp lifted its holdings in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company's stock valued at $15,909,000 after purchasing an additional 405,169 shares during the last quarter. Infinitum Asset Management LLC bought a new position in shares of Y-mAbs Therapeutics in the fourth quarter worth $1,218,000. Finally, Paradigm Biocapital Advisors LP grew its position in shares of Y-mAbs Therapeutics by 3.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock valued at $33,171,000 after purchasing an additional 150,000 shares in the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.